Syndax crossed $100 million in combined net product sales in a single quarter for the first time, but the more telling number is 48% — the share of R/R KMT2A-rearranged patients now proceeding to stem cell transplant after revumenib, up from a prior estimate of 33%. That jump reframes the revenue story entirely. Post-transplant patients frequently return to revumenib as maintenance, meaning each transplant bridges into an additional treatment cycle. Duration of therapy, not new-patient volume, becomes the primary growth lever — and that dynamic is structurally harder for a competitor to erode than simple market share.
Revuforj’s $48.9 million in Q1 net revenue — a 144% year-over-year increase — still carries the franchise narrative, but Niktimvo is the sleeper. Axatilimab generated $55.1 million in gross net revenue in Q1 against a chronic GVHD indication that is, by hematologic disease standards, a narrow market. Syndax captures only a collaboration slice of that figure, but the forthcoming Phase 2 topline readout in frontline chronic GVHD in Q4 2026 represents a genuine label expansion into the largest addressable segment. If that data holds, Niktimvo’s revenue ceiling resets materially upward — and the IPF readout arriving on the same timeline introduces a non-oncology growth vector that most analysts have not priced seriously.
The competitive position in menin inhibition is real but not permanent. Revumenib’s approval preceded rivals, and the transplant-rate data shores up the durable-use argument, but EVOLVE-2 and REVEAL-ND — both randomized, placebo-controlled Phase 3 frontline trials — are the actual moat. First approval in newly diagnosed AML locks in prescriber habit, payer formulary position, and combination-regimen familiarity years before any follow-on asset can replicate the dataset. The multiple combination arms now running with venetoclax, intensive chemotherapy, and gilteritinib are not exploratory hedges; they are systematic efforts to own every major frontline backbone before competitors can run the same studies.
The single number to track from here is the post-HSCT maintenance enrollment rate across Syndax’s City of Hope and multi-center trials. If the transplant conversion rate has genuinely moved to 48% and is still rising, maintenance uptake will be the revenue line that surprises consensus estimates most — and the one that determines whether revumenib’s commercial trajectory sustains double-digit quarterly growth into 2027.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
